8-K: Zivo Bioscience Issues Shares in Private Transactions and Exchange Program

Zivo Bioscience issued 191,698 shares of common stock through private sales, restricted stock grants, and an exchange program.

Summary

• Zivo Bioscience issued a total of 191,698 shares of its common stock in transactions not involving a public offering.
• 75,000 shares were sold to an accredited investor at $20.19 per share, generating gross proceeds of over $1.5 million.
• 38,478 shares were granted as restricted stock to non-employee board members under the 2024 Equity Incentive Plan.
• 78,320 shares were issued to investors as part of an Exchange Program, canceling certain License and Co-Development Participation Agreements.
• As of January 20, 2025, the company has 3,738,033 shares of common stock outstanding.
• The shares were issued without registration under the Securities Act of 1933, relying on exemptions for private placements.

Sentiment

Score: 6

Explanation: The document reports on routine capital raising activities and stock grants, which are neither particularly positive nor negative. The company is executing on its strategy, but there is no significant news that would dramatically impact the stock.

Positives

• The company successfully raised over $1.5 million through a private placement.
• The Exchange Program simplifies the company's financial structure by canceling certain agreements.
• The issuance of restricted stock aligns the interests of non-employee directors with the company's performance.

Risks

• The issuance of new shares dilutes existing shareholders' ownership.
• The company is relying on exemptions from registration, which may limit future fundraising options.

Industry Context

Private placements and stock-based compensation are common practices for emerging growth companies to raise capital and incentivize key personnel.

Comparison to Industry Standards

• Many small-cap biotech companies use private placements to raise capital, often at a discount to the market price.
• Granting restricted stock to board members is a standard practice to align their interests with shareholders.
• The use of an exchange program to simplify agreements is not uncommon in corporate restructuring.

Stakeholder Impact

• Existing shareholders will experience dilution due to the issuance of new shares.
• Accredited investors who purchased shares will have an ownership stake in the company.
• Non-employee directors will have increased equity ownership through restricted stock grants.

Key Dates

Keywords

equity, shares, private placement, restricted stock, exchange program, capital raise, accredited investor, dilution